PON1 status in haemodialysis patients and the impact of hepatitis C infection.

[1]  O. Erel,et al.  Oxidative stress in hepatitis C infected end-stage renal disease subjects , 2006, BMC infectious diseases.

[2]  B. Coll,et al.  Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. , 2006, Journal of hepatology.

[3]  I. Çelik,et al.  Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. , 2005, World journal of gastroenterology.

[4]  B. Coll,et al.  Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[5]  J. Kastelein,et al.  Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400052-JLR200 , 2005, Journal of Lipid Research.

[6]  D. Shih,et al.  The paraoxonase gene family and atherosclerosis. , 2005, Free radical biology & medicine.

[7]  R. Manfro,et al.  The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  E. Sarandol,et al.  Serum paraoxonase activity in uremic predialysis and hemodialysis patients. , 2004, Journal of nephrology.

[9]  U. John,et al.  Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. , 2004, Atherosclerosis.

[10]  J. Yodoi,et al.  Elevation of blood thioredoxin in hemodialysis patients with hepatitis C virus infection. , 2003, Kidney international.

[11]  A. Yonemura,et al.  R192Q paraoxonase gene variant is associated with a change in HDL-cholesterol level during dietary caloric restriction in nondiabetic healthy males. , 2003, Journal of atherosclerosis and thrombosis.

[12]  A. Girolami,et al.  Chronic viral hepatitis: a prospective factor against atherosclerosis. A study with echo-color Doppler of the carotid and femoral arteries and the abdominal aorta. , 2002, Gastroenterologie clinique et biologique.

[13]  A. Kahraman,et al.  Oxidative stress markers in hepatitis C infected hemodialysis patients. , 2002, Journal of nephrology.

[14]  H. Hashimoto,et al.  Increased Prevalence of Carotid Atherosclerosis in Hepatitis B Virus Carriers , 2002, Circulation.

[15]  J. Joven,et al.  Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. , 2002, Clinical chemistry.

[16]  R. Nagai,et al.  Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening , 2002, The Lancet.

[17]  T. Miyata,et al.  Reactive carbonyl compounds related uremic toxicity ("carbonyl stress"). , 2001, Kidney international. Supplement.

[18]  E. Reiner,et al.  Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. , 2001, Croatian medical journal.

[19]  J. Himmelfarb,et al.  Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. , 2000, Kidney international.

[20]  C. Zoccali,et al.  AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complications. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  V. Carreño,et al.  Role of haemodialysis and hepatitis c virus infection in spontaneous and induced cytokine production of patients with chronic renal disease. , 2000, Cytokine.

[22]  M. J. Cole,et al.  Biological dynamics of viral load in hemodialysis patients with hepatitis C virus , 2000 .

[23]  D. Shih,et al.  The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. , 1999, Chemico-biological interactions.

[24]  B. La Du,et al.  Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. , 1999, Free radical biology & medicine.

[25]  Jeetesh V. Patel,et al.  Serum paraoxonase after myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. Nourooz-Zadeh.  Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. , 1999, Methods in enzymology.

[27]  T. Miyata,et al.  Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.

[28]  G. Paragh,et al.  The Serum Paraoxonase Activity in Patients with Chronic Renal Failure and Hyperlipidemia , 1998, Nephron.

[29]  P. Durrington,et al.  Human serum paraoxonase. , 1998, General pharmacology.

[30]  F. Locatelli,et al.  Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  J. Hokanson,et al.  Paraoxonase genotypes, lipoprotein lipase activity, and HDL. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[32]  D. Giavarina,et al.  Serum paraoxonase activity is decreased in uremic patients. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[33]  C. Loughrey,et al.  Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. , 1995, Clinical chemistry.

[34]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[35]  A. Brock,et al.  A New Automated Method for Phenotyping Arylesterase (EC 3.1.1.2) Based Upon Inhibition of Enzymatic Hydrolysis of 4-Nitrophenyl Acetate by Phenyl Acetate , 1992, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[36]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.